Parslew Richard, Traulsen Jette
Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool L69 3BX, England.
Eur J Dermatol. 2005 Jan-Feb;15(1):37-9.
The proportion of elderly patients with psoriasis vulgaris is set to increase in the future due to an ageing population. This descriptive analysis assessed the efficacy and safety of a new ointment containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet in a pooled analysis of patients aged 60 years and over. A total of 1534 patients, including 357 aged > or = 60 years, with psoriasis vulgaris received the two-compound ointment once-daily in four randomised, double-blind, studies. After 4 weeks treatment the mean reduction in PASI was 67.8% in patients < 60 years compared with 72.6% in patients > or = 60 years. "Controlled disease" (i.e. a global assessment of "absence of disease" or "very mild disease"), according to the investigators, was achieved by 52.1% of patients < 60 years and 58.2% of patients > or = 60 years. Patients in both age groups reported a similar number of lesional/perilesional adverse drug reactions; 6.4% in patients < 60 years vs 5.0% in patients > or = 60 years. Thus, the new two-compound ointment is effective and well-tolerated in the treatment of psoriasis vulgaris, regardless of age group.
由于人口老龄化，寻常型银屑病老年患者的比例未来将有所增加。本描述性分析评估了一种含卡泊三醇和二丙酸倍他米松的新软膏（在一项汇总分析中为达力士倍他米松软膏/得肤宝）对60岁及以上患者的疗效和安全性。共有1534例寻常型银屑病患者，包括357例年龄≥60岁的患者，在四项随机、双盲研究中接受了这种复方软膏每日一次的治疗。治疗4周后，年龄<60岁患者的银屑病面积和严重程度指数（PASI）平均降低67.8%，而年龄≥60岁患者为72.6%。根据研究者的评估，年龄<60岁的患者中有52.1%、年龄≥60岁的患者中有58.2%达到了“疾病得到控制”（即整体评估为“无疾病”或“非常轻度疾病”）。两个年龄组患者报告的皮损/皮损周围药物不良反应数量相似；年龄<60岁患者为6.4%，年龄≥60岁患者为5.0%。因此，这种新的复方软膏在治疗寻常型银屑病方面有效且耐受性良好，与年龄组无关。
